Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Conglomerates sector higher today making it today's featured conglomerates winner. The sector as a whole closed the day up 1.3%. By the end of trading, 3M rose $1.25 (1.1%) to $114.67 on average volume. Throughout the day, 1,988,173 shares of 3M exchanged hands as compared to its average daily volume of 2,421,700 shares. The stock ranged in a price between $113.34-$114.89 after having opened the day at $113.58 as compared to the previous trading day's close of $113.42. Other companies within the Conglomerates sector that increased today were:

MGT Capital Investments



), up 5.6%,

EveryWare Global



), up 5.2% and

AcelRx Pharmaceuticals



Scroll to Continue

TheStreet Recommends

), up 5.0%.

3M Company operates as a diversified technology company worldwide. 3M has a market cap of $78.9 billion and is part of the conglomerates industry. Shares are up 22.2% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate 3M a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the conglomerates sector could consider

SPDR Trust Series 1



) while those bearish on the conglomerates sector could consider

ProShares Short S&P 500




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.